Epidermal growth factor prevents gut atrophy and maintains intestinal integrity in rats with acute pancreatitis

Table 1 Composition of TPN solution (mL)

Composition	Volume
50% glucose	40
7% vamin*	16
20% intralipid*	11
Addamel*	0.3
Soluvit N*	0.3
Vitalipid N adult*	0.3
Heparin 60 U

*Products from Kabi Vitrum, Sweden.

Table 2 Changes in mucosal wet mass, villus height and area (x^-± s, n = 8)

t/d	Group	m (wet mucosa)/mg·cm-1	h (villus)/μm2	a (villus)/μm
1	Control	35 ± 3	385 ± 32	40872 ± 5194
	EGF	35 ± 4	394 ± 37	41328 ± 4901
5	Control	30 ± 2	272 ± 21	18658 ± 2469
	EGF	44 ± 3b	409 ± 32b	43227 ± 5340b

^bP < 0.01, vs control group at same time.

Table 3 Changes in plasma FITC-dextran (x^-± s, n = 8, mg·L^-1)

t/d	Group	FITC-dextran
1	Control	1.2 ± 0.5
	EGF	1.1 ± 0.4
5	Control	7.5 ± 0.7
	EGF	3.3 ± 0.7b

^bP < 0.01, vs control group at same time.

Table 4 Changes in activities of MPO, sucrase and maltase (x^-± s, n=8)

t/d	Group	z/m (MPO)/nkat·g-1	z/m (sucrase)/nkat·g-1	z/m (maltase)/nkat·g-1
1	Control	143.34 ± 111.67	0.54 ± 0.11	1.75 ± 0.32
	EGF	231.19 ± 8.34	0.49 ± 0.02	1.82 ± 0.21
5	Control	96.68 ± 13.35	0.19 ± 0.05	0.84 ± 0.16
	EGF	66.71 ± 13.20b	0.28 ± 0.08a	1.23 ± 0.24b

^aP < 0.05,

^bP < 0.01 vs control group at same time.